ClinicalTrials.gg
TerminatedNCT00424775Updated Apr 20, 2015Results posted

A Study of Carboplatin + Paclitaxel and MK0683 in Patients With Chemotherapy-naive Non-Small Cell Lung Cancer (NSCLC)(0683-066)

A Phase 1 interventional study of MK0683, vorinostat in Neoplasms, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2015-04-20.

Primary conditionCarcinoma, Non-Small-Cell LungRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Non-Small-Cell Lung
Why
  1. The study's title name Carcinoma, Non-Small-Cell Lung, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
3
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing vorinostat in Carcinoma, Non-Small-Cell Lung — none open to participants now, 1 under way, none of them phase 3. Vorinostat · Carcinoma, Non-Small-Cell Lung.

Enrollment
19th of 19
3 · median 21
Started
2007
with 4 others
Phase 1
11 of 20
none open now
Registered
7th of 20
by date
Lead sponsor
6 of 20
Merck Sharp & Dohme LLC

Among the 20 studies testing vorinostat in Carcinoma, Non-Small-Cell Lung, this one is the 19th largest by enrollment of the 19 interventional ones that give a count, is one of 5 that started in 2007, is one of 11 in phase 1, and was the 7th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

None of the 20 studies testing vorinostat in Carcinoma, Non-Small-Cell Lung is open now. The open studies under Carcinoma, Non-Small-Cell Lung, anywhere →

Where they have run

About vorinostat

Vorinostat: first FDA approval 2006 (ZOLINZA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies testing vorinostat in Carcinoma, Non-Small-Cell Lung as a file.
02

Study summary

The clinical study will evaluate safety, tolerability and Pharmacokinetics of MK0683 in combination with carboplatin and paclitaxel in chemotherapy-naive NSCLC patients.

03

Conditions studied

  • Neoplasms

Browse trials for

Keywords

  • Non-Small Cell Lung Cancer (NSCLC)
04

In context

Carcinoma, Non-Small-Cell Lung Reclassified

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

This study's enrollment of 3 is below the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.

Browse Carcinoma, Non-Small-Cell Lung studies →

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Compared within Carcinoma, Non-Small-Cell Lung, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chemotherapy-naive patients who are or cytologically diagnosed NSCLC with stage IIIB (not applicable of radical thoracic radiation) or stage IV
  • Patients with normal organ function and bone marrow function

Exclusion criteria

Exclusion Criteria:

  • Given radical thoracic radiation for NSCLC or radiation for other than original lesion within 3 weeks
  • Any peripheral neuropathy above grade 2
  • Any ascites, pleural effusion or pericardiac effusion which requires treatment
  • Any uncontrolled concomitant illness
  • Pregnant or breast-feeding
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Interventions

  • vorinostat 300 mg or 400 mg once daily consecutive days (14 days) followed by 11 days of rest in the first cycle or 7 days of rest in the second or later cycle.

    Also known as: MK0683

07

What researchers measure

Primary outcomes

  1. Number of Participants With a Dose Limited Toxicity at First Cycle

    Dose Limited Toxicity = Drug-related side effects that are serious enough to prevent an increase in dose or level of that treatment.

    Time frame: 25 Days (first cycle)

Secondary outcomes

  1. Area Under the Curve (AUC(0-24 hr)) at Day 4

    Area Under the Curve (AUC (0-24 hr)) = Area under the plasma concentration versus time curve (AUC) from time zero to 24 hour.

    Time frame: Day 4

  2. Area Under the Curve (AUC(0-24 hr)) at Day 5

    Area Under the Curve (AUC (0-24 hr)) = Area under the plasma concentration versus time curve (AUC) from time zero to 24 hour.

    Time frame: Day 5

  3. Maximum Concentration (Cmax) at Day 4

    Maximum Concentration (Cmax) = the maximum plasma concentration of the drug

    Time frame: Day 4

  4. Maximum Concentration (Cmax) at Day 5

    Maximum Concentration (Cmax) = the maximum plasma concentration of the drug

    Time frame: Day 5

08

Results

Posted Jun 1, 2009

Participant flow

Date of first participant in: 26 January 2007. Data of last participant's last visit in study protocol: 7 March 2007. The study was conducted at single center in Japan.

Participant flow — Overall Study
MilestoneVorinostat (300 mg)Vorinostat (400 mg)
Started30
Completed00
Not completed30
Withdrew: Adverse event20
Withdrew: Lack of efficacy10

Outcome measures

PrimaryNumber of Participants With a Dose Limited Toxicity at First Cycle

Dose Limited Toxicity = Drug-related side effects that are serious enough to prevent an increase in dose or level of that treatment.

Time frame:
25 Days (first cycle)
Reported as:
Number · Participants
Number of Participants With a Dose Limited Toxicity at First Cycle
ParticipantsVorinostat (300 mg)
Number of Participants With a Dose Limited Toxicity at First Cycle3
SecondaryArea Under the Curve (AUC(0-24 hr)) at Day 4

Area Under the Curve (AUC (0-24 hr)) = Area under the plasma concentration versus time curve (AUC) from time zero to 24 hour.

Time frame:
Day 4
Reported as:
Mean · µM hr
Area Under the Curve (AUC(0-24 hr)) at Day 4
µM hrVorinostat (300 mg)
Area Under the Curve (AUC(0-24 hr)) at Day 49.76 (6.61 to 12.90)
SecondaryArea Under the Curve (AUC(0-24 hr)) at Day 5

Area Under the Curve (AUC (0-24 hr)) = Area under the plasma concentration versus time curve (AUC) from time zero to 24 hour.

Time frame:
Day 5
Reported as:
Mean · µM hr
Area Under the Curve (AUC(0-24 hr)) at Day 5
µM hrVorinostat (300 mg)
Area Under the Curve (AUC(0-24 hr)) at Day 56.26 (5.37 to 7.14)
SecondaryMaximum Concentration (Cmax) at Day 4

Maximum Concentration (Cmax) = the maximum plasma concentration of the drug

Time frame:
Day 4
Reported as:
Mean · µM
Maximum Concentration (Cmax) at Day 4
µMVorinostat (300 mg)
Maximum Concentration (Cmax) at Day 41.54 (0.99 to 2.09)
SecondaryMaximum Concentration (Cmax) at Day 5

Maximum Concentration (Cmax) = the maximum plasma concentration of the drug

Time frame:
Day 5
Reported as:
Mean · µM
Maximum Concentration (Cmax) at Day 5
µMVorinostat (300 mg)
Maximum Concentration (Cmax) at Day 51.96 (1.60 to 2.32)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vorinostat (300 mg)—0/3 (0%)—
Most frequent other events
Most frequent other events
EventVorinostat (300 mg)
AnaemiaBlood and lymphatic system disorders2/3
LeukopeniaBlood and lymphatic system disorders2/3
LymphopeniaBlood and lymphatic system disorders2/3
DiarrhoeaGastrointestinal disorders2/3
NauseaGastrointestinal disorders2/3
VomitingGastrointestinal disorders2/3
FatigueGeneral disorders2/3
PyrexiaGeneral disorders2/3
AnorexiaMetabolism and nutrition disorders2/3
Neutrophil count decreasedInvestigations2/3

Baseline characteristics

Age, Continuous
Age, Continuous(years)Vorinostat (300 mg)
Mean64 ± 2.0
Sex: Female, Male
Sex: Female, Male(Participants)Vorinostat (300 mg)
Female1
Male2
09

Study locations

No study locations are listed for this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2007, a primary completion of Mar 2007 and a completion of Mar 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2009, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2007
First posted
Jan 22, 2007
Start
Jan 2007
Primary completionActual
Mar 2007
CompletionActual
Mar 2007
Results first posted
Jun 1, 2009
Last update
Apr 20, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00424775
Responsible party
Sponsor
First posted
Jan 22, 2007
Start date
Jan 2007
Primary completion
Mar 2007
Completion
Mar 2007
Results posted
Jun 1, 2009
Last update
Apr 20, 2015

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vorinostat

Start the discussion